Your browser doesn't support javascript.
loading
Gut microbial ß-glucuronidases regulate host luminal proteases and are depleted in irritable bowel syndrome.
Edwinson, Adam L; Yang, Lu; Peters, Stephanie; Hanning, Nikita; Jeraldo, Patricio; Jagtap, Pratik; Simpson, Joshua B; Yang, Tzu-Yi; Kumar, Praveen; Mehta, Subina; Nair, Asha; Breen-Lyles, Margaret; Chikkamenahalli, Lakshmikanth; Graham, Rondell P; De Winter, Benedicte; Patel, Robin; Dasari, Surendra; Kashyap, Purna; Griffin, Timothy; Chen, Jun; Farrugia, Gianrico; Redinbo, Matthew R; Grover, Madhusudan.
Affiliation
  • Edwinson AL; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
  • Yang L; Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
  • Peters S; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
  • Hanning N; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
  • Jeraldo P; Laboratory of Experimental Medicine and Pediatrics and Infla-Med, research center of excellence, University of Antwerp, Antwerp, Belgium.
  • Jagtap P; Department of Surgery, Mayo Clinic, Rochester, MN, USA.
  • Simpson JB; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.
  • Yang TY; Department of Chemistry, University of North Carolina, Chapel Hill, NC, USA.
  • Kumar P; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.
  • Mehta S; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.
  • Nair A; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.
  • Breen-Lyles M; Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
  • Chikkamenahalli L; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
  • Graham RP; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
  • De Winter B; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Patel R; Laboratory of Experimental Medicine and Pediatrics and Infla-Med, research center of excellence, University of Antwerp, Antwerp, Belgium.
  • Dasari S; Division of Gastroenterology and Hepatology, Antwerp University Hospital, Edegem, Belgium.
  • Kashyap P; Division of Clinical Microbiology, Mayo Clinic, Rochester, MN, USA.
  • Griffin T; Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
  • Chen J; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
  • Farrugia G; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.
  • Redinbo MR; Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
  • Grover M; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Nat Microbiol ; 7(5): 680-694, 2022 05.
Article in En | MEDLINE | ID: mdl-35484230
Intestinal proteases mediate digestion and immune signalling, while increased gut proteolytic activity disrupts the intestinal barrier and generates visceral hypersensitivity, which is common in irritable bowel syndrome (IBS). However, the mechanisms controlling protease function are unclear. Here we show that members of the gut microbiota suppress intestinal proteolytic activity through production of unconjugated bilirubin. This occurs via microbial ß-glucuronidase-mediated conversion of bilirubin conjugates. Metagenomic analysis of faecal samples from patients with post-infection IBS (n = 52) revealed an altered gut microbiota composition, in particular a reduction in Alistipes taxa, and high gut proteolytic activity driven by specific host serine proteases compared with controls. Germ-free mice showed 10-fold higher proteolytic activity compared with conventional mice. Colonization with microbiota samples from high proteolytic activity IBS patients failed to suppress proteolytic activity in germ-free mice, but suppression of proteolytic activity was achieved with colonization using microbiota from healthy donors. High proteolytic activity mice had higher intestinal permeability, a higher relative abundance of Bacteroides and a reduction in Alistipes taxa compared with low proteolytic activity mice. High proteolytic activity IBS patients had lower fecal ß-glucuronidase activity and end-products of bilirubin deconjugation. Mice treated with unconjugated bilirubin and ß-glucuronidase-overexpressing E. coli significantly reduced proteolytic activity, while inhibitors of microbial ß-glucuronidases increased proteolytic activity. Together, these data define a disease-relevant mechanism of host-microbial interaction that maintains protease homoeostasis in the gut.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Irritable Bowel Syndrome / Gastrointestinal Microbiome Limits: Animals / Humans Language: En Journal: Nat Microbiol Year: 2022 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Irritable Bowel Syndrome / Gastrointestinal Microbiome Limits: Animals / Humans Language: En Journal: Nat Microbiol Year: 2022 Document type: Article Affiliation country: Country of publication: